Version 1
: Received: 7 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (09:20:25 CEST)
How to cite:
Hassan, S. S.; Pal Choudhury, P.; Roy, B. SARS-CoV2 Envelope Protein: Non-Synonymous Mutations and Its Consequences. Preprints2020, 2020060072. https://doi.org/10.20944/preprints202006.0072.v1
Hassan, S. S.; Pal Choudhury, P.; Roy, B. SARS-CoV2 Envelope Protein: Non-Synonymous Mutations and Its Consequences. Preprints 2020, 2020060072. https://doi.org/10.20944/preprints202006.0072.v1
Hassan, S. S.; Pal Choudhury, P.; Roy, B. SARS-CoV2 Envelope Protein: Non-Synonymous Mutations and Its Consequences. Preprints2020, 2020060072. https://doi.org/10.20944/preprints202006.0072.v1
APA Style
Hassan, S. S., Pal Choudhury, P., & Roy, B. (2020). SARS-CoV2 Envelope Protein: Non-Synonymous Mutations and Its Consequences. Preprints. https://doi.org/10.20944/preprints202006.0072.v1
Chicago/Turabian Style
Hassan, S. S., Pabitra Pal Choudhury and Bidyut Roy. 2020 "SARS-CoV2 Envelope Protein: Non-Synonymous Mutations and Its Consequences" Preprints. https://doi.org/10.20944/preprints202006.0072.v1
Abstract
In the NCBI database, as on June 6, 2020, total number of available complete genome sequences of SARS-CoV2 across the world is 3617. The envelope protein of SARS-CoV2 possesses several non-synonymous mutations over the transmembrane domain and (C)-terminus in 0.414\% of these 3617 genomes. The C-terminus motif DLLV has been changed to DFLV and YLLV in the proteins QJR88103 (Australia: Victoria) and QKI36831 (China: Guangzhou) respectively, which might affect the binding of this motif with the host protein PALS1.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
19 December 2021
Commenter:
Wayne Miller
The commenter has declared there is no conflict of interests.
Comment:
I am wondering if you can point to any very current publications that address the issue of nucleocapsid protein mutations in the latest SARS CoV II varients? Thank you.
Commenter: Wayne Miller
The commenter has declared there is no conflict of interests.